Bicara Therapeutics Inc. 8-K

What Happened
Bicara Therapeutics Inc. announced on January 12, 2026 (via an 8‑K, Item 8.01) that it has selected the optimal dose for its Phase 3 program and provided a corporate outlook for 2026. The company issued a press release titled “Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook,” which is attached to the filing as Exhibit 99.1. The 8‑K was signed by CEO Claire Mazumdar, Ph.D.

Key Details

• Date filed: January 12, 2026 (Form 8‑K, Item 8.01).
• Announcement: Selection of Phase 3 optimal dose and release of a 2026 corporate outlook (press release attached as Exhibit 99.1).
• Exhibit: Press release included as Exhibit 99.1 to the filing.
• Signature: Filing signed by Claire Mazumdar, Ph.D., Chief Executive Officer.

Why It Matters
Selecting an optimal Phase 3 dose and issuing a corporate outlook are operational milestones that inform investors about the status and near‑term plans of Bicara’s clinical program(s). The press release attached to this 8‑K is the company’s public disclosure of those updates; the filing itself does not include additional financial statements or numeric financial guidance. Investors should review the attached press release for details on timelines, planned milestones, and any program‑specific information.